Comparative Pharmacology
Head-to-head clinical analysis: DEXTROMETHORPHAN POLISTIREX versus TUXARIN ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROMETHORPHAN POLISTIREX versus TUXARIN ER.
DEXTROMETHORPHAN POLISTIREX vs TUXARIN ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextromethorphan polistirex is an NMDA receptor antagonist and sigma-1 receptor agonist. It inhibits serotonin reuptake and acts on the brain stem cough center to elevate the threshold for coughing.
TUXARIN ER contains dextromethorphan, an NMDA receptor antagonist and sigma-1 receptor agonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor. The combination is thought to modulate glutamatergic neurotransmission and enhance dopaminergic and noradrenergic signaling.
30-60 mg orally every 12 hours; not to exceed 120 mg in 24 hours.
1 tablet orally every 12 hours; each tablet contains chlorpheniramine maleate 8 mg and phenylephrine HCl 20 mg.
None Documented
None Documented
Terminal half-life: 13–19 hours; clinical context: extended-release formulation due to polistirex complex; time to steady-state: ~3 days
The terminal elimination half-life (t1/2) of chlorpheniramine is approximately 14–25 h in adults, allowing twice-daily dosing. Pseudoephedrine has a shorter t1/2 of 5–8 h in normal renal function, but the ER formulation maintains therapeutic levels for 12 h. In renal impairment, pseudoephedrine half-life prolongs significantly, requiring dose adjustment.
Renal: ~45% as unchanged drug and metabolites (dextrorphan conjugates); fecal: <2%; biliary: minimal
TUXARIN ER is a combination antihistamine/decongestant. The antihistamine component (e.g., chlorpheniramine) is extensively metabolized via CYP450; its metabolites and parent drug (∼68% over 48 h) appear in urine as unchanged drug and metabolites. The decongestant (e.g., pseudoephedrine) is primarily excreted unchanged in urine (∼70–90%) with the remainder metabolized in liver; renal elimination is pH-dependent, with acidic urine increasing excretion. Fecal elimination is negligible (<5%).
Category C
Category C
Antitussive
Antitussive/decongestant combination